Let's not forget what a compelling indication RD could be for a partner. RD could be a very nice little business for the right company.
For handicapping probable partnership outcomes, we need to think about both sides of the equation: trial results on one side, and the potential RD market on the other hand.
If trial results leave a reasonable chance that ampakines could work out for RD, are pharma's going to let a competitor take the rights without putting up a fight?
News 
Market Data 
Discover 
AI
